JPMorgan Chase & Co. Raises Merck & Co., Inc. (NYSE:MRK) Price Target to $93.00

Merck & Co., Inc. (NYSE:MRK) had its price objective increased by JPMorgan Chase & Co. from $90.00 to $93.00 in a report released on Friday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 12.33% from the company’s previous close.

A number of other brokerages have also issued reports on MRK. BMO Capital Markets upped their target price on shares of Merck & Co., Inc. from $83.00 to $84.00 and gave the company a “market perform” rating in a research note on Wednesday, May 1st. ValuEngine lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. UBS Group increased their price objective on shares of Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reiterated a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a research note on Friday, March 29th. Finally, Atlantic Securities upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a research note on Monday, May 13th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $83.79.

Shares of Merck & Co., Inc. stock traded down $0.11 during trading on Friday, reaching $82.79. The company had a trading volume of 121,762 shares, compared to its average volume of 8,654,134. The firm has a market cap of $215.52 billion, a PE ratio of 19.08, a price-to-earnings-growth ratio of 1.99 and a beta of 0.55. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.06 and a current ratio of 1.37. Merck & Co., Inc. has a fifty-two week low of $59.80 and a fifty-two week high of $84.27.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, April 30th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.17. The business had revenue of $10.82 billion for the quarter, compared to analyst estimates of $10.45 billion. Merck & Co., Inc. had a net margin of 19.50% and a return on equity of 39.85%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.05 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 4.72 earnings per share for the current year.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 192,736 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $82.05, for a total value of $15,813,988.80. Following the completion of the transaction, the chairman now owns 990,451 shares in the company, valued at approximately $81,266,504.55. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Merck & Co., Inc. bought 4,121,683 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was purchased at an average price of $16.00 per share, with a total value of $65,946,928.00. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 445,308 shares of company stock worth $36,421,320. 0.27% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC lifted its stake in Merck & Co., Inc. by 2.2% during the first quarter. Global Retirement Partners LLC now owns 6,120 shares of the company’s stock valued at $509,000 after purchasing an additional 131 shares during the last quarter. O Brien Wealth Partners LLC lifted its stake in Merck & Co., Inc. by 4.2% during the first quarter. O Brien Wealth Partners LLC now owns 3,281 shares of the company’s stock valued at $273,000 after purchasing an additional 133 shares during the last quarter. MONECO Advisors LLC lifted its stake in Merck & Co., Inc. by 4.9% during the first quarter. MONECO Advisors LLC now owns 2,916 shares of the company’s stock valued at $243,000 after purchasing an additional 135 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Merck & Co., Inc. by 2.4% during the first quarter. Lindbrook Capital LLC now owns 5,858 shares of the company’s stock valued at $487,000 after purchasing an additional 136 shares during the last quarter. Finally, Condor Capital Management lifted its stake in Merck & Co., Inc. by 3.0% during the first quarter. Condor Capital Management now owns 4,624 shares of the company’s stock valued at $385,000 after purchasing an additional 136 shares during the last quarter. Hedge funds and other institutional investors own 75.17% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: What is the Moving Average Convergence Divergence (MACD) oscillator?

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply